Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.

Trial Details

NCT ID
NCT06492837
Phase
PHASE2
Sponsor
Fondazione Italiana Linfomi - ETS
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Mosunetuzumab in combination with Zanubrutinib
Locations (sample)
  • Adelaide, Australia|-34.92866,138.59863
  • Liverpool, Australia|-33.91938,150.92588
  • Melbourne, Australia|-37.814,144.96332
  • Woolloongabba, Australia|-27.48855,153.03655
  • Candiolo, Torino, Italy|44.95858,7.59812

Key Eligibility Criteria

  • Able to provide written informed consent form approved by the National Ethics Committee (NEC) prior to the initiation of any screening or study-spe…
  • Histologically documented diagnosis of cFL (CD20+ by flow cytometry or immunohistochemistry) as defined in the International Consensus Classificati…
  • Age ≥18 years.
  • Relapsed or refractory disease. Histologic confirmation of FL relapse is not mandatory but is highly recommended.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →